JAFRON announced its performance forecast on the evening of January 21, expecting a net profit attributable to the parent company of 800 million to 860 million yuan in 2024, a year-on-year increase of 83% to 97%. During the reporting period, the external policy environment for the company improved to some extent. The company continues to leverage its technological and market leadership in the field of blood perfusion, with good business development trends in areas such as nephrology, hepatology, and critical care. This has resulted in a year-on-year increase in the company's operating revenue. The company conducts various business activities based on the principle of increasing efficiency and reducing costs, leading to a year-on-year decrease in the period expense ratio, and thus a significant year-on-year increase in net profit attributable to shareholders of the listed company